---
layout: default
title: Mefloquine
parent: 僅模型預測 (L5)
nav_order: 296
evidence_level: L5
indication_count: 0
---

# Mefloquine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Mefloquine (DB00358): Drug Repurposing Analysis — No Predictions Available

## One-Sentence Summary

Mefloquine is an antimalarial agent (DrugBank ID: DB00358) currently not marketed in Canada.
This Evidence Pack **contains no TxGNN repurposing predictions** and has critical data gaps across indication, MOA, and safety fields.
A formal drug repurposing evaluation cannot be completed without supplementary data collection.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not documented in this Evidence Pack |
| Predicted New Indication | No predictions returned |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no predictions generated |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Mefloquine is a quinoline-methanol antimalarial agent (DrugBank ID: DB00358); however, since neither original indications nor MOA data are present in the supplied Evidence Pack, a formal mechanistic analysis linking the original indication to a new indication cannot be conducted.

The TxGNN prediction pipeline did not return any repurposing candidates for this drug in the current run. This may result from incomplete input mapping (e.g., DrugBank ID not resolving to a knowledge graph node), a missing disease-drug edge in the training graph, or a pipeline upstream error. The `query_log` confirms only one successful DrugBank query was executed, and no collector sources (ClinicalTrials, PubMed, etc.) were queried.

Until a prediction is available and the above data gaps are resolved, it is not possible to assess whether Mefloquine's mechanism is applicable to any new indication.

---

## Safety Considerations

Please refer to the package insert for safety information.

> The Evidence Pack reports `[Data Gap]` for all of: key warnings, contraindications, and drug interactions. No DDI records were found (query_status: `not_found`). Safety data must be retrieved before any downstream evaluation proceeds.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Mefloquine contains blocking data gaps — no TxGNN repurposing predictions were generated, original indication and MOA data are absent, and no safety profile is available. Proceeding to any repurposing evaluation under these conditions would be methodologically unsound.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve the package insert (from Health Canada Product Monograph or equivalent) to extract key warnings and contraindications; this must be resolved before safety screening can begin
- **[High — DG002]** Query DrugBank API for Mefloquine (DB00358) to obtain MOA, pharmacodynamics, and toxicity data
- **Re-run TxGNN predictions** for Mefloquine — verify that DB00358 is correctly mapped to a knowledge graph node and that the prediction pipeline completes without errors; check `data/processed/repurposing_candidates.csv` for output
- **Populate original indications** — Mefloquine's approved indication (antimalarial) should be retrieved from Health Canada's Drug Product Database and documented in the Evidence Pack
- **Expand collector queries** — run ClinicalTrials.gov, PubMed, and DrugBank collectors against Mefloquine once predictions are available
- **Verify jurisdiction mapping** — confirm that the `taiwan_regulatory` field is correctly populated with Canadian DIN data (current record shows 0 DINs and no licence entries)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

